查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835254

幽门螺旋桿菌非侵入性检测市场（按检测类型、技术、最终用户和分销管道）－全球预测，2025-2032

Helicobacter Pylori Non-invasive Testing Market by Test Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，非侵入性幽门螺旋桿菌检测市场将成长至 17.8 亿美元，复合年增长率为 5.88%。

主要市场统计数据
基准年2024年 11.2亿美元
预计2025年 11.9亿美元
预测年份：2032年 17.8亿美元
复合年增长率（%） 5.88%

简要介绍非侵入性幽门螺旋桿菌诊断、临床相关性、病患治疗路径以及相关人员不断变化的决策前景

幽门螺旋桿菌的非侵入性检测已成为消化不良、消化性溃疡及相关胃部疾病诊断途径的重要组成部分，这源于人们在保持诊断准确性的同时尽量减少侵入性内视镜操作的需求。这些检测透过提供适合门诊病人工作流程、基层医疗机构和分散式实验室网路的替代方案，提高了患者的便利性并减轻了操作负担。临床医生在选择诊断工具时，越来越重视灵敏度、特异性、週转时间和患者依从性，这些因素正在影响整个医疗保健系统的采购和临床路径决策。

随着技术和临床指南的不断发展，非侵入性诊断的决策格局也在改变。付款人和医疗系统需要证据将检测策略与患者结果和下游资源利用联繫起来。因此，製造商和实验室必须提供清晰的临床检验、与现有设备的操作相容性，以及将结果整合到电子健康记录的途径。这些趋势旨在扩大非侵入性检测作为适当临床环境中一线诊断工具的作用，同时保留用于复杂或难治病例的内视镜检测。

技术创新、检测分散化以及临床指引的变化如何重塑医疗环境中的非侵入性幽门螺旋桿菌诊断

随着技术进步、分散式医疗模式以及注重准确性和患者便利性的更新临床指南的融合，非侵入性幽门螺旋桿菌检测的格局正在改变。免疫测量平台的快速改进，加上质谱和光谱分析方法的进步，正在提升分析性能并缩短週转时间。同时，数位化工作流程和远端检体采集正在将检测范围从传统的医院实验室扩展到基层医疗机构和居家医疗机构，从而影响临床医生的采用和患者的参与。

监管部门对临床检验和可重复性的重视，促使製造商投资于强有力的证据方案，而付款方的审查则加速了对健康经济合理性的需求。随着临床医师逐渐适应非侵入性治疗方案，医疗路径的平衡正被重新平衡。低风险患者越来越多地采用依赖高性能非侵入性检测的「检测-治疗」策略进行管理，而内视镜检查则仅用于高风险或诊断可疑的病例。这种系统转变为能够证明临床严谨性、易用性以及与分散式检测环境相容性的诊断服务提供者创造了新的机会。

评估 2025 年美国新关税对诊断相关人员、定价动态和策略采购的连锁影响。

美国2025年实施的新关税立即对整个诊断供应链产生了连锁反应，改变了采购行为和策略采购决策。某些检测耗材、设备和组件的进口关税上调，增加了许多中小型实验室的到岸成本，促使采购团队重新评估其供应商组合，并优先考虑拥有本地生产设施和替代物流策略的供应商。这种转变导致实验室更加重视供应链透明度和合约弹性，以降低价格波动并维持病患服务的连续性。

为了应对这种情况，一些製造商加快了近岸外包，并实现了供应商多元化，以降低跨境贸易摩擦的风险。对于依赖专用试剂和仪器组件的诊断开发商而言，关税使得他们更加重视长期供应商关係和垂直整合，并将其作为风险规避策略。同时，付款人和医疗保健采购委员会也更加关​​注整体拥有成本，包括缺货和前置作业时间奖励，并投资于区域供应弹性，从而保障临床的连续性并维持可靠的非侵入性检测的可及性。

跨测试类型、技术、最终用户和分销管道的高级细分洞察揭示了临床采用、采购行为和创新路径

了解市场动态需要采用多层次的细分方法，将测试效能与临床用例和采购逻辑连结。依测试类型，有血清学测试、粪便抗原测试和尿素呼吸检测。血清学测试细分为 IgA、IgG 和 IgM 检测，而粪便抗原测试包括单株和多多株抗体方法。虽然血清学测试很方便，但它们可能反映过去的暴露，而不是活动性性行为感染。由于单克隆和多克隆抗体试剂化学性质的差异，粪便抗原测试可提供活动性性行为感染的直接证据，而尿素呼气测试如果操作正确，可以以非侵入性的方式确认活动性性行为感染，并且特异性很强。

从技术角度来看，市场涵盖免疫检测平台、红外线光谱和质谱。免疫检测选项进一步细分为 ELISA 和快速免疫检测，而质谱则以 GC-MS 和 LC-MS 为代表。每种技术类别都需要在通量、灵敏度、仪器占地面积和资本强度之间进行权衡。最终用户包括诊所、诊断实验室和医院。诊所分为胃肠病诊所和基层医疗诊所，医院分为二级和三级医疗中心。分销管道正在不断发展，包括线下和线上通路。线上通路支援将套件直接销售给消费者，并为机构买家快速补货。整合这些细分视角可以明确临床需求和采购标准的交汇点，以及创新可以在哪些方面提供差异化的临床和营运价值。

美洲、中东和非洲以及亚太地区的区域动态和差异化招募模式

非侵入性幽门螺旋桿菌检测的区域动态受医疗保健基础设施、报销标准、临床实践模式和法律规范差异的影响。美洲地区在门诊病人网路和综合医疗保健系统中越来越多地采用经过验证的非侵入性诊断方法，并积极努力使检测途径与初级保健工作流程保持一致。在欧洲、中东和非洲，由于法规环境和报销政策的差异，一些市场正在迅速采用先进技术，而其他市场则优先考虑能够满足基本诊断需求的经济高效的检测方法。

随着人们对胃肠道疾病流行病学认识的不断提高、诊断检测能力的不断提升以及对即时医疗服务的重视，亚太地区正在加速非侵入性检测方案的普及。製造商和经销商必须根据当地报销惯例和临床医生的偏好，定制其临床证据包、定价模式和服务能力。因此，跨国公司通常会采取差异化的上市策略，与当地实验室和国内分销商合作，以确保符合监管规定，并根据每个细分市场的具体需求客製化产品定位。

非侵入性幽门螺旋桿菌诊断生态系中关键参与者、创新者和专业领域的竞争定位和能力评估

非侵入性幽门螺旋桿菌诊断领域的竞争态势由众多知名仪器製造商、专业试剂供应商以及开发照护现场或分散式解决方案的敏捷创新者共同构成​​。关键竞争因素包括临床检验的深度、分销的广度、服务和培训能力，以及与实验室资讯系统和电子健康记录整合的能力。能够展示稳健性能数据、强大的上市后监测和可靠供应营运的公司将获得采购团队和实验室管理人员的优先事项。

技术创新也在改变竞争定位。对于寻求简化工作流程的诊所和诊断实验室而言，那些投资于多路復用功能、提高检测灵敏度和特异性以及简化样本采集套件的公司越来越有吸引力。仪器製造商和试剂供应商之间的策略伙伴关係，以及与受託研究机构合作进行临床检验，是加速市场渗透的常见策略。此外，提供全面客户支援（包括临床教育和实施服务）的组织通常能够建立超越一次性采购交易的长期组织关係。

诊断生态系领导者必须采取有针对性的策略行动，以加速诊断的采用，确保供应弹性，并优化诊断商业化的临床证据生成

诊断生态系统领导者应优先考虑一系列有针对性的行动，以利用需求变化并降低营运风险。首先，投资符合当地监管要求的严格临床检验研究，可以增强临床医生的信心并提高付款人的接受度。这些研究必须证明其在护理过程中具有明确的临床效用，而不仅仅是分析性能。其次，透过近岸外包、双重采购和策略性库存伙伴关係等方式实现製造和供应商关係的多元化，可以减少关税造成的成本衝击和物流中断的风险。

第三，加强数位化和直接面向消费者的管道，将实现高效的检体追踪和结果交付，同时扩大患者的可及性。第四，及早与付款方和卫生技术评估机构沟通，明确报销标准，并提供真实世界证据，将有助于实现可预测的采用。最后，与实验室和临床网路建立合作项目，以进行持续的市场研究和迭代式产品改进，将保持竞争优势。将这些行动结合起来，将创造一个兼顾技术创新、营运可靠性和以付款方为导向的证据产生能力的弹性商业模式。

透过结合临床医生访谈、临床实验室检验、监管映射和三重二手资料的强大调查方法来获得严谨的见解

支持这些发现的研究将定性一手研究与结构化的二次研究以及方法学保障措施相结合，以确保信度和效度。一手研究包括对临床相关人员（包括胃肠病学家、基层医疗医生、实验室主任和采购专业人员）的深入访谈，以了解决策因素、临床工作流程和应用障碍。这些对话指导了对现实世界诊断路径的解读，并有助于确定技术和最终用户的重点领域，以便进一步研究。

二次研究涵盖同行评审文献、监管指南文件、技术白皮书和製造商技术规范，以支持临床和技术声明。监管图谱确定了国家核准途径和上市后要求，而对近期专利申请和学术论文的审查则阐明了技术创新的轨迹。数据合成依靠三角测量来协调来源之间的不一致，并建构连贯的叙述。品质保证步骤包括对关键发现进行专家检验，以及对主题结论进行敏感性检查，以确保建议在不同的临床和营运环境下均具有稳健性。

综合策略意义、临床发展动能和市场准备情况，强调非侵入性幽门螺旋桿菌检测相关人员的关键要点

幽门螺旋桿菌的非侵入性诊断技术正处于曲折点，技术进步、医疗服务分散化以及监管力度的加强正在共同重塑临床实践。检测效能的提升、可及途径的拓展以及付款人对临床效用日益增长的兴趣，共同为将非侵入性检测更一致地纳入诊断方案创造了条件。相关人员协调临床检验、供应弹性和付款人参与的利害关係人，将最有可能影响医疗保健途径，并确保其在不同医疗环境中持续应用。

展望未来，持续重视证据生成和操作与实际临床实务的整合，将决定哪些技术能获得长期临床应用。积极满足临床医生需求、简化工作流程并展示非侵入性检测以患者为中心的优势的製造商和实验室，很可能获得最广泛的受众。最终，最成功的策略将是那些在科学严谨性与成本、可及性和易实施性等实际因素之间取得平衡的策略，从而为患者提供更好的治疗结果，并为医疗保健提供者提供更可预测的运作。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 越来越多地采用智慧型手机整合尿素呼吸检测来快速检测门诊幽门螺旋桿菌
  • 扩大多重粪便抗原检测以提高菌株鑑别和抗生素抗药性分析的敏感度
  • 人工智慧预测演算法的出现，可以解释非侵入性测试结果并预测治疗结果
  • 开发一种针对幽门螺旋桿菌的 POC层析法检测方法，以提高资源有限地区的准确性和成本效益
  • 粪便 DNA 甲基化分析在幽门螺旋桿菌感染非侵入性检测和个人化管理的应用日益广泛
  • 在低至中等盛行率族群中，非侵入性诊断途径与内视镜检查相比的成本效益分析
  • 采用非放射性同位素技术的新型呼吸检测套件的监管核准和打入市场策略

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 幽门螺旋桿菌非侵入性检测市场（依检测类型）

  • 血清学检测
    • IGa测试
    • 免疫球蛋白G检测
    • IGm测试
  • 粪便抗原检测
    • 单株抗体检测
    • 多株抗体检测
  • 尿素呼气试验

9. 幽门螺旋桿菌非侵入性检测市场（依技术）

  • 免疫检测
    • 伊丽莎
    • 快速免疫检测
  • 红外线光谱
  • 质谱法
    • GC-MS
    • LC-MS

第 10 章。非侵入性幽门螺旋桿菌检测市场（按最终用户）

  • 诊所
    • 胃肠病诊所
    • 基层医疗诊所
  • 诊断实验室
  • 医院
    • 二级护理医院
    • 三级医院

第 11 章。非侵入性幽门螺旋桿菌检测市场（按分销管道）

  • 离线
  • 在线的

12. 幽门螺旋桿菌非侵入性检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章。 幽门螺旋桿菌无创检测市场（按组）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 幽门螺旋桿菌非侵入性检测市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • bioMerieux SA
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • QIAGEN NV
    • DiaSorin SpA
    • Meridian Bioscience, Inc.
    • SD BIOSENSOR Co., Ltd.
Product Code: MRR-437E9896A586

The Helicobacter Pylori Non-invasive Testing Market is projected to grow by USD 1.78 billion at a CAGR of 5.88% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.12 billion
Estimated Year [2025] USD 1.19 billion
Forecast Year [2032] USD 1.78 billion
CAGR (%) 5.88%

A concise orientation to non-invasive Helicobacter pylori diagnostics, clinical relevance, patient pathways, and the evolving decision landscape for stakeholders

Non-invasive testing for Helicobacter pylori has become a pivotal component of diagnostic pathways for dyspepsia, peptic ulcer disease, and related gastric disorders, driven by the need to minimize invasive endoscopic procedures while preserving diagnostic accuracy. These tests improve patient convenience and reduce procedural burden by offering alternatives that are compatible with outpatient workflows, primary care settings, and decentralized laboratory networks. Clinicians increasingly weigh sensitivity, specificity, turnaround time, and patient adherence when selecting a diagnostic modality, and these factors shape procurement and clinical pathway decisions across healthcare systems.

As technology and clinical guidelines evolve, the decision landscape for non-invasive diagnostics is also shifting. Payers and health systems seek evidence that links testing strategies to patient outcomes and downstream resource utilization. Consequently, manufacturers and laboratories must present clear clinical validation, operational compatibility with existing instrumentation, and pathways to integrate results into electronic health records. Together, these trends are aligning to expand the role of non-invasive testing as a first-line diagnostic tool in appropriate clinical scenarios, while preserving endoscopy for complex or refractory cases.

How technological innovation, decentralization of testing, and changing clinical guidelines are reshaping non-invasive Helicobacter pylori diagnosis across care settings

The landscape of non-invasive Helicobacter pylori testing is being transformed by a convergence of technological advances, decentralized care models, and updated clinical guidance that privileges precision and patient convenience. Rapid improvements in immunoassay platforms, coupled with advances in mass spectrometry and spectrometric approaches, are enhancing analytical performance while enabling shorter turnaround times. Simultaneously, digital workflows and remote specimen collection are expanding access beyond traditional hospital laboratories and into primary care and home-based settings, which in turn influences clinician adoption and patient engagement.

Regulatory emphasis on clinical validation and reproducibility is encouraging manufacturers to invest in robust evidence packages, and payer scrutiny is accelerating the demand for health-economic justification. As clinicians adapt to non-invasive alternatives, pathways of care are being rebalanced: patients with low-risk presentations are increasingly managed with test-and-treat strategies that rely on high-performing non-invasive assays, while endoscopy is conserved for high-risk or ambiguous cases. These systemic shifts are creating new opportunities for diagnostics providers who can demonstrate clinical rigor, ease of use, and compatibility with decentralized testing environments.

Assessing the cascading effects of new United States tariff measures enacted in 2025 on supply chains, pricing dynamics, and strategic sourcing for diagnostics stakeholders

The introduction of new tariff measures in the United States in 2025 had immediate ripple effects across the diagnostics supply chain, altering procurement behavior and strategic sourcing decisions. Increased import duties on certain laboratory consumables, instruments, and components elevated landed costs for many small and mid-sized laboratories, prompting procurement teams to re-evaluate supplier portfolios and prioritize vendors with local manufacturing footprints or alternative logistics strategies. These shifts have placed a premium on supply chain transparency and contractual flexibility as laboratories seek to mitigate price volatility and maintain continuity of patient-facing services.

In response, some manufacturers accelerated nearshoring and diversified supplier bases to reduce exposure to cross-border trade frictions. For diagnostic developers that rely on specialized reagents or instrumentation components, the tariffs intensified the focus on long-term supplier relationships and vertical integration as risk-reduction tactics. Meanwhile, payers and provider procurement committees have become more attentive to the total cost of ownership, including the operational impacts of stockouts and lead-time variability. Overall, the tariff environment has strengthened incentives to de-risk sourcing, optimize inventory strategies, and invest in regional supply resilience to protect clinical continuity and preserve access to reliable non-invasive testing.

Nuanced segmentation insight across test types, technologies, end users, and distribution channels illuminating clinical adoption, procurement behavior, and innovation pathways

Understanding market dynamics requires a layered segmentation approach that links test performance to clinical use cases and procurement logic. By test type, offerings span serology tests, stool antigen tests, and urea breath tests; serology is sub-segmented into IgA, IgG, and IgM assays, while stool antigen methodologies include monoclonal and polyclonal antibody approaches. Each test type carries distinct clinical attributes: serology can be convenient but may reflect past exposure rather than active infection, stool antigen assays offer direct evidence of active infection with variations between monoclonal and polyclonal reagent chemistry, and urea breath tests provide non-invasive confirmation of active infection with robust specificity when conducted appropriately.

From a technology perspective, the market encompasses immunoassay platforms, infrared spectrometry, and mass spectrometry, with immunoassay options further divided into ELISA and rapid immunoassay modalities, and mass spectrometry techniques represented by GC-MS and LC-MS approaches. Each technological class presents trade-offs between throughput, sensitivity, equipment footprint, and capital intensity. End users include clinics, diagnostic laboratories, and hospitals; clinics segment into gastroenterology clinics and primary care clinics, while hospitals can be classified as secondary care and tertiary care institutions. Distribution channels are evolving and include both offline and online routes, with online channels enabling direct-to-consumer kit distribution and rapid supply replenishment for institutional buyers. Integrating these segmentation lenses clarifies where clinical demand intersects with procurement criteria and where innovation can yield differentiated clinical and operational value.

Regional dynamics and differentiated adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform commercial and clinical strategies

Regional dynamics in non-invasive Helicobacter pylori testing are shaped by differences in healthcare infrastructure, reimbursement norms, clinical practice patterns, and regulatory frameworks. In the Americas, there is strong uptake of validated non-invasive diagnostics within outpatient networks and integrated health systems, accompanied by active efforts to align testing pathways with primary care workflows. In Europe, Middle East & Africa, heterogeneous regulatory environments and varied reimbursement policies lead to pronounced country-level differences, where some markets adopt advanced technologies rapidly while others prioritize cost-effective assays that meet essential diagnostic needs.

Across the Asia-Pacific region, rising awareness of gastric disease epidemiology, expanding diagnostic laboratory capacity, and an emphasis on point-of-care accessibility are accelerating adoption of non-invasive testing options. These regional distinctions inform go-to-market strategies: manufacturers and distributors must tailor clinical evidence packages, pricing models, and service capabilities to local reimbursement realities and clinician preferences. Consequently, global players often pursue differentiated launch approaches, partnering with regional laboratories or in-country distributors to ensure regulatory alignment and to adapt product positioning to the specific needs of each market cluster.

Competitive positioning and capability assessment of leading players, innovators, and niche specialists in non-invasive Helicobacter pylori diagnostics ecosystems

Competitive dynamics in the non-invasive Helicobacter pylori diagnostics space are defined by a mix of established instrument manufacturers, specialized reagent suppliers, and agile innovators developing point-of-care or decentralizable solutions. Key competitive levers include the depth of clinical validation, the breadth of distribution networks, service and training capabilities, and the ability to integrate with laboratory information systems and electronic health records. Companies that can demonstrate robust performance data, strong post-market surveillance, and reliable supply operations gain preferential consideration from procurement teams and laboratory directors.

Innovation is also reshaping competitive positioning: firms that invest in multiplexing capabilities, improvements in assay sensitivity and specificity, and streamlined sample collection kits are increasingly attractive to clinics and diagnostic laboratories seeking to simplify workflows. Strategic partnerships between instrument makers and reagent vendors, as well as alliances with contract research organizations for clinical validation, are common strategies to accelerate market penetration. Moreover, organizations that provide comprehensive customer support, including clinical education and implementation services, often secure longer-term institutional relationships that extend beyond single-purchase transactions.

Targeted strategic actions for industry leaders to accelerate adoption, secure supply resilience, and optimize clinical evidence-generation for diagnostics commercialization

Leaders in the diagnostics ecosystem should prioritize a set of targeted actions to capitalize on shifting demand and to mitigate operational risks. First, investing in rigorous clinical validation studies that align with local regulatory expectations will accelerate clinician trust and payer acceptance; these studies should demonstrate not only analytical performance but also clear clinical utility within care pathways. Second, diversifying manufacturing and supplier relationships-whether through nearshoring, dual sourcing, or strategic inventory partnerships-will reduce exposure to tariff-induced cost shocks and logistical disruptions.

Third, strengthening digital and direct-to-consumer channels can expand patient access while enabling efficient specimen tracking and result delivery. Fourth, engaging early with payers and health technology assessment bodies to clarify reimbursement criteria and to present real-world evidence will support predictable adoption. Finally, establishing collaborative programs with laboratories and clinical networks for ongoing post-market surveillance and iterative product improvement will sustain competitive differentiation. Taken together, these actions create a resilient commercial model that balances innovation with operational reliability and payer-aware evidence generation.

Robust research methodology combining clinician interviews, laboratory validation review, regulatory mapping, and triangulated secondary intelligence for rigorous findings

The research underpinning these insights combines qualitative primary engagement, structured secondary review, and methodological safeguards to ensure reliability and relevance. Primary research included in-depth interviews with clinical stakeholders such as gastroenterologists, primary care physicians, laboratory directors, and procurement professionals to capture decision drivers, clinical workflows, and adoption barriers. These conversations informed the interpretation of real-world diagnostic pathways and guided the selection of technology and end-user focus areas for deeper investigation.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, technical white papers, and manufacturer technical specifications to corroborate clinical and technical assertions. Regulatory mapping identified local approval pathways and post-market requirements, while a review of recent patent filings and academic publications highlighted innovation trajectories. Data synthesis relied on triangulation across sources to reconcile discrepancies and to build a coherent narrative. Quality assurance steps included expert validation of key findings and sensitivity checks on thematic conclusions to ensure that recommendations remain robust across diverse clinical and operational contexts.

Synthesis of strategic implications, clinical momentum, and market readiness that distills key takeaways for stakeholders in non-invasive Helicobacter pylori testing

Non-invasive diagnostics for Helicobacter pylori are at an inflection point where technological improvements, decentralized care delivery, and heightened regulatory scrutiny converge to reshape clinical practice. The combined momentum of improved assay performance, expanded access pathways, and payer attention to clinical utility creates conditions for more consistent incorporation of non-invasive tests into diagnostic algorithms. Stakeholders that align clinical validation, supply resilience, and payer engagement will be best positioned to influence care pathways and to secure durable adoption across diverse healthcare settings.

Looking ahead, continued emphasis on real-world evidence generation and operational integration will determine which technologies achieve long-term clinical traction. Manufacturers and laboratories that proactively address clinician needs, streamline workflows, and demonstrate the patient-centered benefits of non-invasive testing will find the most receptive audiences. Ultimately, the most successful strategies will balance scientific rigor with practical considerations of cost, access, and ease of implementation to support better outcomes for patients and more predictable operational performance for healthcare providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of smartphone integrated urea breath tests for rapid Helicobacter pylori detection in outpatient settings
  • 5.2. Expansion of multiplex stool antigen assays with enhanced sensitivity for strain differentiation and antibiotic resistance profiling
  • 5.3. Emergence of AI powered predictive algorithms to interpret noninvasive test results and forecast treatment efficacy
  • 5.4. Development of point of care immunochromatographic tests for Helicobacter pylori with improved accuracy and affordability in resource limited regions
  • 5.5. Increasing incorporation of stool DNA methylation analysis for noninvasive detection and personalized management of Helicobacter pylori infection
  • 5.6. Cost effectiveness analysis of noninvasive diagnostic pathways compared to endoscopy in low to moderate prevalence populations
  • 5.7. Regulatory approvals and market entry strategies for novel breath test kits utilizing non radioactive isotope technology

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Helicobacter Pylori Non-invasive Testing Market, by Test Type

  • 8.1. Serology Test
    • 8.1.1. IGa Test
    • 8.1.2. IGg Test
    • 8.1.3. IGm Test
  • 8.2. Stool Antigen Test
    • 8.2.1. Monoclonal Antibody Test
    • 8.2.2. Polyclonal Antibody Test
  • 8.3. Urea Breath Test

9. Helicobacter Pylori Non-invasive Testing Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Elisa
    • 9.1.2. Rapid Immunoassay
  • 9.2. Infrared Spectrometry
  • 9.3. Mass Spectrometry
    • 9.3.1. Gc Ms
    • 9.3.2. Lc Ms

10. Helicobacter Pylori Non-invasive Testing Market, by End User

  • 10.1. Clinics
    • 10.1.1. Gastroenterology Clinic
    • 10.1.2. Primary Care Clinic
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
    • 10.3.1. Secondary Care Hospital
    • 10.3.2. Tertiary Care Hospital

11. Helicobacter Pylori Non-invasive Testing Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Helicobacter Pylori Non-invasive Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Helicobacter Pylori Non-invasive Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Helicobacter Pylori Non-invasive Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. bioMerieux SA
    • 15.3.4. Danaher Corporation
    • 15.3.5. Thermo Fisher Scientific Inc.
    • 15.3.6. Siemens Healthineers AG
    • 15.3.7. QIAGEN N.V.
    • 15.3.8. DiaSorin S.p.A.
    • 15.3.9. Meridian Bioscience, Inc.
    • 15.3.10. SD BIOSENSOR Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EU